TherapeuticsMD announced a $125 million stock offering as the women’s health company aims to commercialize its latest drug. ther

The Boca Raton-based company (NYSE: TXMD) has yet to price the common stock offering. It said the underwriters would have a 30-day option to purchase an additional 15 percent of the shares of common stock.

TherapeuticsMD said it’ll use the money mostly to fund commercialization of TX-004HR, an estradoil softgel that the company believes can relieve vaginal pain during sexual intercourse due to vulvar and vaginal atrophy for women in menopause. The company, led by CEO Robert G. Finizio, recently reported positive Phase 3 clinical results for the drug. It plans to file a New Drug Application with the FDA in the first half of this year.

The company already sells vitamins for women’s health. It’s also conducting a clinical trial for a combination estradoil and progesterone drug to treat the vasomotor symptoms of menopause.

TherapeuticsMD lost $67.6 million on revenue of $14.5 million in the first nine months of 2015.

The joint book-running managers of the offering are Goldman, Sachs & Co. and Cowen and Co. Stifel and Guggenheim Securities are the co-managers of the offering.

Shares of TherapeuticsMD were down 63 cents, or 6.8 percent, to $8.68 in pre-market trading on Wednesday.